Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases

Authors

  • Julien Loubinoux,

    Corresponding author
    1. Laboratoire de Bactériologie–Virologie UMR CNRS 7565, Faculté de Médecine, 54505 Vandoeuvre-lès-Nancy Cedex, France
    2. Instituto de Tecnologia Quimica e Biologica, Universidade Nova de Lisboa, 2780-156 Oeiras, Portugal
    Search for more papers by this author
  • Jean-Pierre Bronowicki,

    1. Service d'Hépato-Gastro-Entérologie, Hôpital de Brabois-Adultes, CHU de Nancy, 54511 Vandoeuvre-lès-Nancy Cedex, France
    Search for more papers by this author
  • Ines A.C. Pereira,

    1. Instituto de Tecnologia Quimica e Biologica, Universidade Nova de Lisboa, 2780-156 Oeiras, Portugal
    Search for more papers by this author
  • Jean-Louis Mougenel,

    1. Service d'Hépato-Gastro-Entérologie, Hôpital de Brabois-Adultes, CHU de Nancy, 54511 Vandoeuvre-lès-Nancy Cedex, France
    Search for more papers by this author
  • Alain E. Le Faou

    1. Laboratoire de Bactériologie–Virologie UMR CNRS 7565, Faculté de Médecine, 54505 Vandoeuvre-lès-Nancy Cedex, France
    Search for more papers by this author

*Corresponding author. Service de Microbiologie, Hôpital Hôtel Dieu, 1 Place du Parvis Notre-Dame, 75181 Paris Cedex 04, France. Tel.: +33 1 42 34 82 73; Fax: +33 1 42 34 87 19. j.loubinoux@voila.fr

Abstract

We have searched for sulfate-reducing bacteria in the feces of 41 healthy individuals and 110 patients from a Hepato-Gastro-Enterology Unit using a specific liquid medium (Test-kit Labège®, Compagnie Française de Géothermie, Orléans, France). The 110 patients were separated in 22 patients presenting with inflammatory bowel diseases and 88 patients hospitalized for other lower (n=30) or upper (n=58) digestive tract diseases. Sulfate-reducing bacteria were isolated from 10 healthy individuals (24%), 15 patients presenting with inflammatory bowel diseases (68%), and 33 patients with other symptoms (37%). A multiplex PCR was devised for the identification of Desulfovibrio piger (formerly Desulfomonas pigra), Desulfovibrio fairfieldensis and Desulfovibrio desulfuricans, and applied to the above isolates. The strains of sulfate-reducing bacteria consisted of D. piger (39 isolates), D. fairfieldensis (19 isolates) and D. desulfuricans (one isolate). The prevalence of D. piger was significantly higher in inflammatory bowel disease patients (55%) as compared to healthy individuals (12%) or patients with other symptoms (25%) (P<0.05).

Ancillary